The Regenerative Medicine Market is expected to reach $17.9 billion by 2025, at a CAGR of 15.9%. Market growth is driven by rising investments in regenerative medicine research, and the growing pipeline of regenerative medicine products, and the increase in prevalence of chronic diseases, genetic disorders, and cancer.
Key Players:
3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579
Regenerative Medicine Industry Size, Share and Dynamics
Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer
The incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe, over the last few decades. The increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, can be a result of diabetes and obesity, which will require treatments and incur exorbitant medical expenses.
Opportunity: Implementation of the 21st Century Cures Act
The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, to advance regenerative medicine research and medical innovation this new law has been enacted and covers various provisions that may impact the approval and development of several products in the coming years.
Restraint: High cost of cell and gene therapies
Patients suffering from terminal illnesses and serious disorders requires cell and gene therapies which represent a significant scientific and medical advancement. These therapies are helping to transform how diseases are treated and potentially cured. Furthermore, such therapies will eventually enable doctors and medical professionals to infuse genes/cells via injectable means in order to avoid a series of drugs and multiple surgeries in patients. However, despite the fact of these therapies being lifesavers and more effective compared to the traditional treatments, the response in terms of demand for these therapies is less compared to the anticipation. This can be attributed to the high costs of these therapies and difficulty in obtaining reimbursements and coverage for these therapies.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579
This report categorizes the regenerative medicine market into the following segments and subsegments:
By Product
- Tissue-engineered Products
- Cell Therapies
- Autologous Therapies
- Allogenic Therapies
- Gene Therapies
- Progenitor & Stem Cell Therapies
By Application
- Musculoskeletal
- Oncology
- Wound Care
- Dental
- Ocular
- Other Applications
North America is the largest regional market for regenerative medicine market
The global market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the global market. The growth in the North American global market can be attributed to the expansion of the healthcare sector, and the higher adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases, and rise in stem cell banking, tissue engineering, and drug discovery in the region.
Frequently Asked Questions (FAQ):
What are the recent trends affecting the regenerative medicine market?
Who are the key players in the market, and how intense is the competition?
What are the key applications of regenerative medicine products?
Which region is lucrative for the regenerative medicine market?
Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65442579
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Related Reports:
Cell Culture Media Market:
https://www.marketsandmarkets.com/Market-Reports/cell-culture-media-market-97468536.html
Collagen and Gelatin Market: